Latest Ratios: P/E Ratio -0.3x · EV/EBITDA N/A · ROE -166.6%. (2012–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $3M | $3M | $2M | $47M | $108M | $212M | $268M | $330M | $58M | $105M | $81M |
| Enterprise Value | $842693 | $562840 | $-1908427 | $46M | $106M | $196M | $259M | $312M | $46M | $98M | $77M |
| P/E Ratio → | -0.31 | — | — | — | — | — | — | — | — | — | — |
| P/S Ratio | — | — | — | 42.86 | 34.00 | 6432.73 | 1691.22 | 3669.81 | 487.44 | 701.14 | — |
| P/B Ratio | 0.71 | 0.66 | 0.33 | 2.44 | 2.96 | 4.04 | 4.20 | 9.97 | 3.62 | 9.83 | 11.29 |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | — | — | 41.74 | 33.14 | 5937.97 | 1636.39 | 3470.06 | 386.77 | 654.09 | — |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | — | 100.0% | -423.1% | -44090.9% | -8968.8% | -12409.0% | -5568.0% | -5919.6% | — |
| Operating Margin | — | — | — | -2168.4% | -771.3% | -74954.5% | -15288.4% | -21067.4% | -12230.9% | -11024.6% | — |
| Net Profit Margin | — | — | — | -2093.2% | -658.6% | -70554.5% | -14177.0% | -19343.4% | -11760.4% | -10345.9% | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -166.6% | -166.6% | -180.7% | -82.1% | -47.1% | -40.1% | -46.4% | -70.6% | -105.0% | -173.7% | -114.9% |
| ROA | -104.2% | -104.2% | -128.5% | -44.1% | -30.0% | -35.2% | -40.4% | -57.7% | -82.0% | -127.8% | -83.4% |
| ROIC | -193.9% | -193.9% | -173.9% | -68.7% | -52.7% | -40.7% | -51.8% | -147.8% | -284.4% | -362.5% | -204.9% |
| ROCE | -88.5% | -88.5% | -151.5% | -49.0% | -37.4% | -39.8% | -46.3% | -69.8% | -100.0% | -160.4% | -105.5% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.28 | 0.28 | 0.38 | 0.18 | 0.11 | 0.09 | 0.06 | 0.13 | 0.02 | 0.02 | 0.02 |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | -0.55 | -0.58 | -0.06 | -0.08 | -0.31 | -0.14 | -0.54 | -0.75 | -0.66 | -0.55 |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — | — | — | — |
| Interest Coverage | — | — | — | — | — | — | — | — | — | — | — |
Net cash position: cash ($4M) exceeds total debt ($1M)
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 2.79 | 2.79 | 3.01 | 5.93 | 8.06 | 11.73 | 17.25 | 9.66 | 4.61 | 3.58 | 3.16 |
| Quick Ratio | 2.79 | 2.79 | 3.01 | 5.93 | 8.06 | 11.73 | 17.25 | 9.66 | 4.61 | 3.58 | 3.16 |
| Cash Ratio | 2.73 | 2.73 | 2.73 | 5.25 | 6.72 | 11.41 | 16.45 | 8.97 | 4.38 | 3.28 | 2.84 |
| Asset Turnover | — | — | — | 0.04 | 0.04 | 0.00 | 0.00 | 0.00 | 0.01 | 0.01 | — |
| Inventory Turnover | — | — | — | — | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | — | — | — | — | — | — | — | — | — | — |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% |
| Shares Outstanding | — | $5M | $5M | $4M | $4M | $4M | $4M | $3M | $2M | $2M | $1M |
Immediate liquidity and dilution
As reported in financial statements, Matinas BioPharma's price-to-book ratio of 0.73 suggests the market is pricing the firm at a discount to its net asset value, reflecting deep skepticism regarding the clinical viability of its LNC platform and the company's ability to survive without significant dilution.
The current valuation appears to be driven by the company's precarious cash position rather than the long-term potential of its pipeline. Investors should monitor whether this discount persists, as it may indicate that the market views the intellectual property as having limited liquidation value in a distressed scenario.
Based on recent SEC filings, the company's ROIC has remained deeply negative, reaching -73.6% in 2026Q1, which highlights the structural inability of the current business model to generate returns on invested capital while the firm remains in a pre-revenue, high-burn clinical development phase.
The consistent decay in return metrics suggests that every dollar of capital raised is being consumed by R&D without creating tangible, value-accretive assets. This trend warrants further investigation into whether the LNC platform can eventually reach a commercial inflection point before the capital base is entirely exhausted.
According to the 2026Q1 data, the current ratio has compressed to 1.32, a significant decline from the 6.39 observed in 2024Q2, indicating that the company's ability to meet short-term obligations is rapidly deteriorating as cash reserves are depleted by ongoing clinical trial expenditures.
The rapid contraction of the liquidity buffer suggests that the company may be approaching a point where it must secure external financing to maintain operations. Investors should interpret this as a heightened risk of near-term equity dilution, which could further depress the share price and shareholder value.
As noted in industry research, analysts often misapply P/E or EV/EBITDA ratios to Matinas, which obscures the company's true value as a clinical-stage platform, as these metrics are fundamentally irrelevant for a firm that lacks commercial revenue and is currently burning through its remaining cash reserves.
Instead of earnings-based multiples, investors should focus on the 'cash runway' and the probability-weighted net present value of the clinical pipeline. Relying on traditional valuation metrics for this business model may lead to an incorrect assessment of the company's risk profile and its potential for future growth.
Includes 30+ ratios · 14 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying MTNB stock.
Matinas BioPharma Holdings, Inc.'s current P/E ratio is -0.3x. This places it at the 50th percentile of its historical range.
Matinas BioPharma Holdings, Inc.'s return on equity (ROE) is -166.6%. The historical average is -107.9%.
Based on historical data, Matinas BioPharma Holdings, Inc. is trading at a P/E of -0.3x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.